LATEST UPDATES » Vol 24, No. 07, July 2020 – Mitigating the Impact of COVID-19: How is Food Security Threatened?       » COVID-19 vaccine Reaches Phase I Clinical Trial       » Mathematical Model to Define Eruptive Stages of Young Volcanic Rocks       » Artificial Intelligence to Tackle Agricultural Challenges       » Installation of Mobile X-Ray System at COVID-19 Screening Center in Korea       » World's First Spherical Artificial Eye      
Vol 23, No. 06, June 2019   |   Issue PDF view/purchase
Genetic testing encouraged to prevent ovarian cancer
Women with a family history are encouraged to undergo BRCA1/2 testing for early prevention and detection of ovarian cancer

Doctors are urging women with a family history to get genetic testing to reduce their risk of breast or ovarian cancer, citing Angelina Jolie as a leading example.

In China, about 70 per cent of women with ovarian cancer are not diagnosed until the terminal stage, when the five-year survival rate is only 30 to 40 per cent.

Doctors say testing for mutation of the genes of BRCA1 and BRCA2 can be a useful measure for early screening, especially among those with a family history. BRCA1/2 are closely related with ovarian cancer and breast cancer.

“The risk of ovarian cancer among the general public is 1 percent, while those with a mutation of BRCA1 have the risk of 40 percent and BRCA2 11 to 18 per cent,”said Dr Wu Xiaohua from the Shanghai Cancer Center, which led the nation’s first BRCA1/2 research on ovarian cancer and found 28.5 per cent of Chinese ovarian cancer patients have the BRCA1/2 mutation.

“Angelina Jolie is the most famous case with a family history of the BRCA gene mutation and underwent surgery to remove her ovaries and fallopian tube to prevent cancer,” Wu said.

Doctors said women with a family history of ovarian cancer, or who have shown symptoms of ovarian problems or have certain ovarian diseases should receive BRCA1/2 testing for early prevention and detection of ovarian cancer.

Source: Shine.cn

news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Group
news Twist Bioscience and Proteona Join Hands to Protect Immunocompromised Patients from COVID-19 Infection
news Innovation in Healthcare: IOT-Enabled Tele-Ventilators to Fight Against the COVID-19 Pandemic
news Proteona leads international consortium to develop SARS-CoV-2 neutralizing antibody to help vulnerable immunocompromised individuals

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy